Abstract |
ETB receptor agonist, IRL-1620 (or SPI-1620) presently in US Phase 1 clinical trial, has been demonstrated to selectively and transiently increase tumor blood flow. The present study was conducted to determine the effect of IRL-1620 on radiation therapy in tumor bearing mice inoculated with Dalton's Lymphoma Ascites cells. Tumors were allowed to grow for 30 days to a size of 1.10-1.29 cm3 before starting the treatment. The animals with or without IRL-1620 treatment were exposed to radiation (4 Gy/dose) on every alternate day for a total of 5 doses. Tumor volume was determined twice every week till the end of study. Radiation alone did not affect the tumor volume; however, animals treated with IRL-1620 followed by radiation produced a significant (64%) reduction in tumor volume. Survival of mice improved from 0/10 at 56 days after tumor inoculation in vehicle plus radiation group to 6/10 at 70 days in IRL-1620 (9 nmol/kg) plus radiation group. It is concluded that IRL-1620 improves the efficacy of radiation treatment in tumor bearing mice. (These findings have been earlier presented as an abstract ).
|
Authors | A Gulati, E S Sunila, G Kuttan |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 62
Issue 1
Pg. 14-7
(Jan 2012)
ISSN: 0004-4172 [Print] Germany |
PMID | 22331757
(Publication Type: Journal Article)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Chemical References |
- Endothelins
- Peptide Fragments
- Receptor, Endothelin B
- sovateltide
|
Topics |
- Animals
- Disease Models, Animal
- Endothelins
- Lymphoma
(drug therapy, mortality, pathology, radiotherapy)
- Male
- Mice
- Peptide Fragments
- Receptor, Endothelin B
(agonists)
- Tumor Burden
|